Canada markets open in 5 hours 48 minutes

Addex Therapeutics Ltd (ADDXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.99000.0000 (0.00%)
At close: 10:31AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Addex Announces Participation in the 22nd Bio€quity Europe Conference

    Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 - 18, 2022, in Milan, Italy. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate

  • GlobeNewswire

    Addex Shareholders Approve All Resolutions at Annual General Meeting

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2022 Annual General Meeting (AGM). In line with the Swiss Federal Council COVID-19 Ordinance 3, the company decided to require its shareholders not atten

  • GlobeNewswire

    Addex Reports Q1 2022 Financial Results

    CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson’s disease expected to report data in H1 2023Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in Q4 2022 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutic